临床试验/NCT02302092

NCT02302092终止3 期

A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis

Takeda0 个研究点目标入组 13 人开始时间: 2015年12月1日最近更新: 2017年10月27日

适应症

干预措施

试验速览

阶段: 3 期
状态: 终止
发起方
入组人数: 13
主要终点: Percentage of Participants Who Achieved Resolution of All Clinical Symptoms of a Complicated Urinary Tract Infection (cUTI) at the End of Treatment (EOT) Visit

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to compare the effectiveness of antibiotic flomoxef with cefepime for the treatment of complicated urinary tract infections (cUTIs) in Russian adults.

详细描述

The drug being tested in this study is called Flomoxef. Flomoxef is being tested in people with a complicated urinary tract infection (cUTI) including a kidney infection. This study compares Flomoxef to Cefepime, another antibiotic.

The study enrolled 13 patients.

Participants are randomly assigned by a computer generated number to one of two treatment groups:

Flomoxef - intravenous infusion 2g twice daily (every 12 hours); or
Cefepime - intravenous infusion 1g twice daily (every 12 hours).

This multi-center trial is conducted at 4 sites in the Russian Federation. The overall time to participate in this study is 30+/-3 days. Participants make six visits to the clinic.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Is a man or woman aged 18 to 70 years, inclusive.
•Has pyuria (a white blood cell [WBC] count greater than 10/μL in unspun urine or greater than or equal to 10 per high power field in spun urine).
•Has clinical signs and/or symptoms of a complicated lower urinary tract infection (UTI) and/or acute pyelonephritis that include one or more of the following: fever (i.e, axillary temperature greater than 37.7°C), chills, malaise, flank pain, back pain, and/or costo-vertebral angle pain or tenderness and/or any symptoms of dysuria (dysuria, urinary urgency, urinary frequency, suprapubic discomfort, new urinary incontinence or worsening of pre-existing incontinence) that occur in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of catheterization.
•Has a pretreatment baseline urine culture specimen obtained within 24 hours before the administration of the first dose of study drug (NOTE: Participants may be enrolled in this study and start intravenous (IV) study drug therapy before the Investigator knows the results of the baseline urine culture).
•Requires IV antibacterial therapy for the treatment of the presumed complicated UTI (cUTI).
•In the opinion of the investigator, is capable of understanding and complying with protocol requirements.
•Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures, or has a legally acceptable representative sign the forms.
•Meets protocol-specified criteria regarding the use of contraception; and 9-Is willing and able to comply with study procedures.

排除标准

•Has received any investigational compound within 30 days of screening.
•Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, or sibling) or may consent under duress.
•Is a female participant who is pregnant or lactating or intending to become pregnant before, during, or within one month after participating in this study, or intends to donate ova during such time period.
•Is a male participant who intends to donate sperm during the course of this study or for 12 weeks thereafter.
•Has participated in another clinical study within the past 30 days.
•Has a history of allergy to or intolerance of beta-lactams (penicillins, cephalosporins or carbopenems).
•Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff, 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding), or 3) the analysis of results.
•Has received any amount of potentially therapeutic antibacterial therapy after collection of the pretreatment baseline urine culture and before administration of the first dose of study drug.
•Has received any dose of a potentially therapeutic antibacterial agent for the treatment of the current UTI within 48 hours before providing the pretreatment baseline urine culture specimen.
•Has a current urinary catheter that is not scheduled to be removed before the End-of-Therapy (EOT) visit (intermittent straight catheterization during the IV study drug administration period is acceptable).
•Has any history of trauma to the pelvis or urinary tract within one year before the screening visit.
•Has any other contraindications to the medicines that are to be used in the study (according to the manufacturer's instructions).
•Is considered unlikely to survive the four-week study period or has any rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock).

研究组 & 干预措施

Flomoxef

Experimental

Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.

干预措施: Flomoxef (Drug)

Cefepime

Active Comparator

Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.

干预措施: Cefepime (Drug)

结局指标

主要结局

Percentage of Participants Who Achieved Resolution of All Clinical Symptoms of a Complicated Urinary Tract Infection (cUTI) at the End of Treatment (EOT) Visit

时间窗: Baseline and Days 7 to 14

At the EOT visit (Days 7 to 14), the Investigator collected information about each symptom and performed a judgement about the participant's status. Clinical symptoms present at trial entry were considered to be resolved if the participant has no pyuria; no fever; no malaise, flank pain, back pain, and/or costo-vertebral angle pain or tenderness; and no symptoms of dysuria, urinary urgency, urinary frequency, suprapubic discomfort, new urinary incontinence, or worsening of pre-existing incontinence. Resolution of all clinical symptoms of cUTI were assessed relative to baseline.

次要结局

Percentage of Participants With Microbiological Success at the EOT and Test-of-Cure (TOC) Visits(Baseline, Days 7 to 14 and 14 to 21)
Percentage of Participants With Microbiologic Persistence of the Unique Pathogen at the EOT and TOC Visits(Baseline, Days 7 to 14 and 14 to 21)
Percentage of Participants With a New Infection at the EOT and TOC Visits(Baseline, Days 7 to 14 and 14 to 21)
Percentage of Participants Who Achieved Clinical Resolution of Symptoms of a cUTI at Visit 3, TOC and Late Follow-up (LFU) Visits(Baseline, Days 3, 14 to 21 and 30)
Percentage of Participants With Microbiologic Eradication of the Unique Pathogen at the EOT and TOC Visits(Baseline, Days 7 to 14 and 14 to 21)
Percentage of Participants With a Superinfection at the EOT and TOC Visits(Baseline, Day 7 to 14 and 14 to 21)
Number of Participants With Serious Adverse Events (SAEs) and Treatment-Emergent-Adverse Events (TEAEs)(Baseline up to Day 30)
Number of Participants With Clinically Significant Abnormal Laboratory Values(Day 21)
Number of Participants With Clinically Significant Change in Vital Signs(Day 1 up to Day 21)
Number of Participants With Clinically Significant Change in Physical Examination Findings(Day 1 up to Day 21)

研究者

发起方

Takeda

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

3 期

A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial PneumoniaNosocomial Pneumonia (NP)Ventilator-associated Pneumonia (VAP)

NCT01808092Pfizer969

已完成

3 期

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract InfectionsUrinary Tract InfectionsAcute Pyelonephritis

NCT03840148Venatorx Pharmaceuticals, Inc.661

尚未招募

1 期

Antibiotics in Treatment of Chronic periodontitis

CTRI/2020/03/024163Sri Hasanamba Dental College